More articles from Therapy Metrics and Intervention Posters

You have access
Quality control management of clinical PET/CT cancer trials
Jun Zhang, Nathan Hall, Craig O'Dell, Trevor Teetor, Steffen Sammet, Richard Jacko, Rick Layman and Michael Knopp

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1627;
You have access
First experience in proteasome inhibitor therapy of dedifferentiated, radioiodine negative, somatostatin-receptor negative thyroid cancer
Daniel Putzer, Michael Gabriel, Wolfgang Eisterer, Dorota Kendler, Rupert Prommegger, Ruth Madleitner, Georg Dobrozemsky, Guenther Gastl and Irene Virgolini

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1667;
You have access
Do negative diagnostic 131-I and 124-I scans exclude 131-I as a treatment option in patients with positive thyroglobulin levels?
S Chennupati, Douglas Van Nostrand, Varalakshmi Bandaru and S Moreau

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1668;
You have access
Impact of partial volume correction on serial PET FDG for therapy monitoring
Elisheva Sprung, Martine Klein, Roland Chisin and Nanette Freedman

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1628;
You have access
Retention of Ga-68 iron macroaggregates (GIMA) after intratumoral injection in canine models
Franklin Wong, Kamran Ahrar, Amelia Wong, Osama Mawlawi, Jason Stafford, Brian Wong and Peggy Tinkey

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1646;
You have access
Effect of interferon-alpha on 68Ga-DOTA-Tyr3-Octreotate PET uptake in CA20948 rat tumors
Francois-Xavier Hanin, Stanislas Pauwels, Marion De jong and Francois Jamar

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1640;
You have access
What is the role of F-18 FDG PET within clinical trials for NSCLC stage III?
Michael Schmuecking, R. Baum, V. Prasad, N. Presselt, C. Schneider, J. Leonhardi, K. Hoeffken, K. Mueller, T. Wendt and R. Bonnet

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1651;
You have access
FDG PET/CT predicts extrahepatic metastatic potential for treatment planning and endpoint of liver directed yttrium-90 microsphere therapy of colorectal metastasis
Ching-yee Oliver Wong, Bingfeng Tang, Janice Campbell, Feng Qing, Robert Lewandowski, Joseph Thie, Chi-lai Ho, Vanessa Gates, Michael Savin and Riad Salem

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1661;
You have access
Preliminary study of a biodegradable seed: 32P-chromic phosphate-poly (L-lactide) on its biodegradation, pharmacokinetics of 32P nanoparticles after intratumor implantation
Zi zheng Wang, Feng Wang and Guoqiang Shao

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1645;
You have access
The effectiveness of SPECT/CT in hepatic arterial Tc-99m MAA scan (MAAS) planning prior to hepatic Y-90 microsphere therapy (YT)
Sherif Heiba, Manli Jiang, J Weintraub, F. S. Nowakowski, P. Stangl, Anondo Stangl, Scott Nowakowski, Edward Kim, Karin Knesaurek, Zhuangyu Zhang and Josef Machac

Journal of Nuclear Medicine May 1, 2009, 50 (supplement 2) 1663;

Main menu

User menu

Search

More articles from Therapy Metrics and Intervention Posters

Pages